The abstract is read at the publisher; the summary is JClub's.
tDR-Glu-TTC is significantly upregulated in intestinal tissues, plasma, epithelial cells, and human clinical samples, and its level positively correlates with intestinal I/R injury severity.
- Why it matters: The role of tRNA-derived small RNAs in intestinal ischemia/reperfusion injury is unclear, limiting targeted therapeutic options for this tissue-damaging condition.
- What they did: Using tDR sequencing and functional assays, the study shows tDR-Glu-TTC binds and suppresses ADAR1, impairing adenosine-to-inosine editing of ATG18 and Lamp2, inhibiting autophagy and increasing ROS that promotes TNF pathway-mediated necroptosis.
- The result: Dual targeting with N-acetylcysteine plus tDR-Glu-TTC-antagomir synergistically mitigated I/R-induced intestinal injury in vivo, supporting the ADAR1/autophagy/ROS/necroptosis axis as a therapeutic strategy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.